MASLD Disease

Context

Naruvi Hospitals, Vellore, in collaboration with The Hindu, is organizing a webinar on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). The session aims to raise awareness about this silent yet rising liver disorder linked to lifestyle-related metabolic conditions like obesity, insulin resistance, and Type 2 diabetes. The webinar will be held on Sunday at 11:30 a.m., featuring leading hepatology experts.

What is MASLD?

MASLD (Metabolic dysfunction–associated steatotic liver disease), previously termed Non-Alcoholic Fatty Liver Disease (NAFLD), is a chronic liver condition caused by fat accumulation in the liver not due to alcohol consumption.
It is now classified under the broader umbrella of metabolic disorders.
It is often asymptomatic in early stages, hence termed a “silent liver disease”.

Causes and Risk Factors

MASLD is strongly associated with metabolic syndrome, including:
- Obesity
- Type 2 Diabetes Mellitus
- Hyperlipidemia (High blood lipids)
- Hypertension
- Insulin resistance

Public Health Relevance

India has a rising incidence of lifestyle diseases, making MASLD a major non-communicable disease (NCD) of concern.
Estimated to affect over 25% of the global adult population, with increased prevalence in urban India due to sedentary lifestyles and unhealthy diets.
Early detection and lifestyle modifications (diet, exercise, weight loss) are critical for prevention and management.

Medical and Policy Implications

MASLD, if undetected, can progress to liver fibrosis, cirrhosis, or even hepatocellular carcinoma.
National health policies increasingly emphasize preventive care and NCD screening, which could integrate MASLD diagnostics.
The Indian Council of Medical Research (ICMR) and Ministry of Health may consider MASLD within broader NCD control frameworks in future.